Omaha, NB 9/9/15; Los Angeles, CA 9/10/15—Transgenomic, a publicly held provider of diagnostics technologies, has sold its IC product line, including columns and resins, and related assets to EdgeBio for $2.1 million in cash. EdgeBio, which is owned by investment firm StoneCalibre, manufactures and distributes sample preparation and clean-up products for NGS. The IC business will be renamed Concise Separations and will operate as a division of EdgeBio. “As a division of EdgeBio, we intend to work with the company by increasing investments in R&D, sales and marketing, and ultimately helping them unlock their full potential,” commented Brain Wall, StoneCalibre founder and CEO. “An important part of our revitalization strategy is to selectively monetize noncore legacy businesses and product lines so that we can focus our resources on commercialization of Multiplexed ICE COLD-PCR (MX-ICP) for high-value, high-growth clinical applications, such as liquid biopsies for targeted cancer therapy and patient monitoring,” said Transgenomic President and CEO Paul Kinnon.